Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Horvath, Dennis, Termperton, Nigel, Mayora-Neto, Martin, Da Costa, Kelly, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, Groettrup, Marcus, Hoschuetzky, Heinz, Rohayem, Jacques, ter Meulen, Jan,
Natura: Articolo
Lingua:inglese
Pubblicazione: Philipps-Universität Marburg 2023
Soggetti:
Immunology
Medizin
Biotechnology
Microbiology
Medical sciences Medicine
Accesso online:PDF Full Text
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
No abstracts were found for this record.

Documenti analoghi